Answers are grounded in this paper and cite their sources.
Green tea, derived from Camellia sinensis, is a widely consumed dietary source of bioactive polyphenols. Among its major catechins, epigallocatechin-3-gallate (EGCG) has been studied most extensively in cancer research. This review critically synthesizes phytochemical, molecular, preclinical, epidemiological, clinical, pharmacokinetic, and safety evidence to assess the potential role of green tea catechins in cancer prevention and treatment. Preclinical studies of breast, prostate, colorectal, lung, liver, oral, and hematological cancers indicate that EGCG modulates oxidative stress, inflammatory signaling, proliferation, apoptosis, cell-cycle progression, angiogenesis, epithelial–mesenchymal transition, invasion, metastasis, and epigenetic regulation. Reported molecular targets include the PI3K–AKT–mTOR, MAPK, JAK–STAT, and NF-κB signaling pathways, as well as EGFR and VEGF signaling, BCL-2 family proteins, caspases, matrix metalloproteinases, and enzymes involved in DNA methylation. A systematic review and meta-analysis reported an association between green tea or EGCG exposure and lower overall cancer risk, with variation by cancer type and study design. Clinical evidence for efficacy in established malignancies remains limited, and conventional oncological treatment remains the standard of care. By integrating mechanistic findings with human data, this review identifies gaps in clinical efficacy, pharmacokinetics, and safety that must be addressed before green tea catechins can be incorporated into evidence-based oncology.
No takes yet. Share an insight, caveat, or question.
Khalaf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: